Efficacy, safety and palatability of a new broad-spectrum anthelmintic formulation in dogs.
The efficacy, safety and palatability of a new flavoured chewable anthelmintic tablet were investigated in dogs. The efficacy, based on worm counts, of a single recommended therapeutic dose (RTD) of 5 mg pyrantel + 20 mg oxantel + 5 mg praziquantel/kg bodyweight was assessed in experimental infections (EI) and natural infections (NI) with Trichuris vulpis, Echinococcus granulosus and Toxocara canis. For T vulpis, the efficacy of the treatment was 99.3 per cent in EI (comparing groups of six treated and six control dogs) and 100 per cent in NI (nine treated and nine control dogs). For E granulosus, the efficacy was more than 99.9 per cent in EI (11 treated and 11 control dogs). For T canis, the efficacy was 94.3 per cent in EI (10 treated and 10 control dogs) and 100 per cent in NI (12 treated and 13 control dogs). In a field study, Ancylostoma caninum (11 dogs) and T canis (11 dogs) faecal egg counts were reduced by more than 99 per cent, and in eight dogs with Dipylidium caninum proglotides in the faeces the efficacy was 100 per cent. The tablets were readily consumed by 56 of 64 (87.5 per cent) privately owned dogs. Safety was assessed in groups of six dogs treated either once with twice the RTD, once with six times the RTD, with twice the RTD on three consecutive days, or untreated. There were no significant differences in blood parameters between the groups, and no abnormal clinical findings. Two dogs treated with six times the RTD vomited, but no vomiting was observed when administration was repeated two days later.
Intervet Innovation, Zur Propstei, Schwabenheim, Germany.
K
K
Schmid
N
N
Rohdich
E
E
Zschiesche
D J
DJ
Kok
M J
MJ
Allan
D000818:Animals; D000871:Anthelmintics / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use; D004283:Dog Diseases / Q000188:drug therapy* / Q000469:parasitology; D004285:Dogs; D004351:Drug Resistance; D004359:Drug Therapy, Combination; D005243:Feces / Q000469:parasitology; D005260:Female; D006374:Helminthiasis, Animal / Q000188:drug therapy* / Q000469:parasitology; D008297:Male; D010270:Parasite Egg Count / Q000662:veterinary; D011223:Praziquantel / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D011715:Pyrantel / Q000009:adverse effects / Q000031:analogs & derivatives / Q000494:pharmacology / Q000627:therapeutic use; D013649:Taste; D016896:Treatment Outcome
D000871:Anthelmintics; D011715:Pyrantel; D011223:Praziquantel; C003407:oxantel